Equities

Guardant Health Inc

Guardant Health Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)28.61
  • Today's Change0.02 / 0.07%
  • Shares traded2.78m
  • 1 Year change+20.90%
  • Beta1.1573
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 TissueNext tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.

  • Revenue in USD (TTM)692.26m
  • Net income in USD-512.41m
  • Incorporated2011
  • Employees1.78k
  • Location
    Guardant Health Inc3100 Hanover StreetPALO ALTO 94304United StatesUSA
  • Phone+1 (650) 290-7575
  • Fax+1 (302) 531-3150
  • Websitehttps://guardanthealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
LeMaitre Vascular Inc213.03m41.32m2.34bn614.0057.187.0845.9711.001.821.829.4114.730.59921.117.59346,952.8011.629.0212.669.9368.3465.8319.4015.455.52----40.4119.6912.8845.895.9618.9315.51
Enovis Corp2.00bn-121.38m2.59bn6.55k--0.778717.731.30-2.21-2.1736.4359.610.40231.595.91305,598.20-2.43-0.3569-2.66-0.4156.9648.19-6.03-1.061.120.98890.2876--9.22-4.89-40.29--11.91--
UFP Technologies Inc461.85m54.21m2.65bn3.09k49.288.0439.365.737.007.0059.6442.890.88964.186.15149,320.4010.449.6912.0010.9528.3126.3311.7410.141.4313.440.39180.0013.0816.007.5025.7114.08--
Irhythm Technologies Inc560.03m-150.66m2.71bn2.00k--37.70--4.83-4.85-4.8518.042.290.8312.568.79280,012.50-22.33-21.92-26.27-26.7767.8369.39-26.90-25.756.12-24.180.90--19.9027.32-6.24--50.82--
LivaNova PLC1.24bn23.68m2.80bn2.90k121.222.1441.312.260.42590.425922.8124.130.51192.476.42428,185.900.9777-6.011.12-7.4267.7866.991.91-13.562.872.460.3234--12.890.8278120.34---1.64--
TransMedics Group Inc401.09m32.64m2.89bn584.0091.5813.7557.217.190.93890.938911.606.250.54393.565.32686,797.904.43-16.084.78-17.9559.3465.378.14-40.477.33--0.7078--158.5379.3630.92--225.12--
Quidelortho Corp2.83bn-1.86bn2.94bn7.10k--0.925--1.04-27.79-27.7942.3547.300.3722.589.15399,239.40-24.4011.34-27.5112.9147.8962.71-65.6020.930.79290.78950.44690.00-8.2141.83-101.84--45.87--
Inari Medical Inc574.50m-78.58m3.01bn1.30k--6.91--5.24-1.35-1.359.907.440.92211.597.46441,921.50-12.61-0.5941-15.24-0.669686.8289.06-13.68-0.62951.40--0.00--28.73135.4094.41--52.46--
Envista Holdings Corp2.50bn-1.34bn3.51bn12.80k--1.14--1.40-7.77-7.7714.5117.860.41064.216.19195,570.30-21.931.94-25.272.3454.2057.65-53.425.291.773.130.31630.00-0.1012-2.04-142.10---4.22--
Neogen Corp912.20m-23.53m3.52bn2.92k--1.1237.323.86-0.1086-0.10864.2114.470.20132.715.98312,718.20-0.51931.38-0.53461.4449.5648.23-2.584.312.791.030.22150.0012.3717.4158.81--50.02--
Guardant Health Inc692.26m-512.41m3.53bn1.78k------5.11-4.24-4.245.70-0.4880.4153.687.81389,126.50-30.72-22.26-35.19-24.5960.3164.62-74.02-97.075.85-8.041.06--25.4544.1426.76--0.2786--
Axonics Inc431.90m-5.66m3.60bn797.00--5.42527.598.33-0.108-0.1088.5213.000.6021.077.74541,909.70-0.7889-12.67-0.848-13.7676.5970.04-1.31-29.686.40--0.00--33.86249.0689.80--23.65--
DENTSPLY SIRONA Inc3.90bn-413.00m3.62bn15.00k--1.43--0.9283-2.07-2.0718.9112.530.56412.945.91260,000.00-5.93-1.14-7.41-1.3252.1853.65-10.51-2.510.84443.210.471--1.10-0.107186.11---4.549.86
ICU Medical Inc2.30bn-70.79m4.32bn14.00k--2.1227.531.87-2.92-2.9294.9083.430.52672.1314.68164,591.20-1.621.46-1.831.6532.4734.11-3.072.231.080.55550.44120.00-0.915410.0460.08---1.45--
Haemonetics Corporation1.33bn114.89m4.47bn3.66k39.164.9420.503.352.232.2325.9217.700.59241.877.05364,751.205.105.025.746.0753.5851.748.618.112.3360.200.57470.0012.016.231.8716.40-11.04--
Integer Holdings Corp1.68bn114.44m4.59bn10.50k42.172.8320.732.733.243.2247.8748.330.55944.935.14160,023.803.813.284.103.5327.0626.946.816.402.094.110.40280.0016.035.6238.719.3321.71--
Data as of Nov 08 2024. Currency figures normalised to Guardant Health Inc's reporting currency: US Dollar USD

Institutional shareholders

49.06%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 202411.28m9.17%
Wellington Management Co. LLPas of 30 Sep 202410.13m8.23%
BlackRock Fund Advisorsas of 30 Jun 20248.42m6.84%
Deep Track Capital LPas of 02 Oct 20246.58m5.35%
Baillie Gifford & Co.as of 30 Sep 20245.87m4.77%
Capital Research & Management Co. (International Investors)as of 30 Jun 20244.47m3.63%
Eventide Asset Management LLCas of 30 Jun 20243.76m3.06%
Temasek Holdings Pte Ltd. (Investment Management)as of 30 Jun 20243.75m3.05%
Cadian Capital Management LPas of 30 Jun 20243.13m2.55%
Citadel Advisors LLCas of 30 Jun 20242.96m2.41%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.